Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial.

@article{Ruzicka2004OralA,
  title={Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial.},
  author={Thomas Ruzicka and Frederik Gr{\o}nh{\o}j Larsen and Dorota Galewicz and Attila Horv{\'a}th and Pieter Jan Coenraads and Kristian thestrup-pedersen and J‐P. Ortonne and Christos C. Zouboulis and Martin Harsch and T Brown and Maurice Zultak},
  journal={Archives of dermatology},
  year={2004},
  volume={140 12},
  pages={
          1453-9
        }
}
OBJECTIVE To assess the efficacy and safety of oral alitretinoin (9-cis-retinoic acid), 10 mg/d, 20 mg/d, and 40 mg/d, compared with placebo control, in the treatment of chronic hand dermatitis. DESIGN Multicenter, randomized, double-blind, placebo-control, prospective trial. SETTING A total of 43 outpatient clinics in 10 European countries. PATIENTS Of 348 patients screened, 319 with moderate or severe refractory chronic hand dermatitis were randomized, in the ratio of 1:1:1:1, to 4… Expand

Paper Mentions

Interventional Clinical Trial
The purpose of this study is to investigate the safety and efficacy of alitretinoin in the treatment of severe chronic hand eczema that does not respond to treatment with potent… Expand
ConditionsEczema
InterventionDrug
Interventional Clinical Trial
The purpose of the study is to determine the therapeutic effect of alitretinoin, a retinoid, on severe, therapy refractory chronic hand dermatitis.  
ConditionsHand Dermatoses
InterventionDrug
Interventional Clinical Trial
Patients with severe chronic hand dermatitis, that has not responded to topical treatment, including topical steroids and the avoidance of aggravating factors, will be treated with the… Expand
ConditionsHand Dermatoses
InterventionDrug
Interventional Clinical Trial
Patients who have been treated in study protocol BAP089 may have responded to treatment, and subsequently relapsed to >75% of the baseline disease severity, will be investigated for… Expand
ConditionsHand Dermatoses
InterventionDrug
[Response to treatment with oral alitretinoin in patients with chronic hand eczema that is refractory to treatment with potent topical corticosteroids: experience in 15 patients].
TLDR
The results of this study support the proposal of alitretinoin as an effective and safe short-term and medium-term treatment for chronic hand eczema in patients whose disease is refractory to treatment with potent topical corticosteroids. Expand
Response to Treatment With Oral Alitretinoin in Patients With Chronic Hand Eczema That Is Refractory to Treatment With Potent Topical Corticosteroids: Experience in 15 Patients ☆
TLDR
The results of this study support the proposal of alitretinoin as an effective and safe short-term and medium-term treatment for chronic hand eczema in patients whose disease is refractory to treatment with potent topical corticosteroids. Expand
Alitretinoin as a potential advance in the management of severe chronic hand eczema.
TLDR
Oral alitretinoin at a dose of 10 or 30 mg once daily is an effective and safe treatment for severe chronic hand eczema refractory to topical corticosteroids and a patient global assessment of “clear” or “almost clear” at the end of therapy is found. Expand
[Alitretinoin in chronic hand eczema: summary of clinical trials].
  • M. Richard
  • Medicine
  • Annales de dermatologie et de venereologie
  • 2010
TLDR
Alitretinoin treatment can be envisaged as second-line therapy in adults with CHE that does not respond to well-observed treatment with class potent or very potent dermocorticoids. Expand
Effective Treatment of Chronic Hand Dermatitis with 36 Continuous Months of Alitretinoin Administration: Report of Three Cases
TLDR
Alitretinoin was well tolerated in the treatment of these three CHD patients who were carefully monitored over this prolonged treatment period with occasional dosage adjustments. Expand
Alitretinoin: in severe chronic hand eczema.
TLDR
Alitretinoin was generally well tolerated in clinical trials excluding pregnant women, and the most common treatment-emergent adverse events and abnormal laboratory test results were consistent with those previously observed with other oral retinoids and RXR agonists. Expand
Study protocol: efficacy of oral alitretinoin versus oral cyclosporine A in patients with severe recurrent vesicular hand eczema (ALICsA): a randomised prospective open-label trial with blinded outcome assessment
TLDR
This is an investigator-initiated randomised prospective open-label trial with blinded outcome assessment to compare efficacy of alitretinoin and cyclosporine in the treatment of severe recurrent vesicular hand eczema. Expand
Efficacy and safety of oral alitretinoin (9‐cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double‐blind, placebo‐controlled, multicentre trial
Background  Patients with severe chronic hand eczema (CHE) refractory to topical corticosteroids currently have limited treatment options suited for chronic use, and few controlled clinical studiesExpand
[Alitretinoin: a new treatment option for chronic refractory hand eczema].
  • S. Molin, T. Ruzicka
  • Medicine
  • Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • 2008
TLDR
Alitretinoin is a promising new option for systemic treatment for chronic hand eczema with detailed patient counseling and appropriate laboratory monitoring. Expand
Efficacy and Safety of Alitretinoin Therapy in Korean Elderly Patients with Chronic Hand Eczema: A Retrospective Single Center Study
TLDR
Alitretinoin can be considered a safe and effective treatment option in elderly patients with moderate to severe CHE and is retrospectively evaluated with respect to laboratory testing. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 22 REFERENCES
Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema.
TLDR
Low-dose cyclosporine at 3 mg/kg/day is as effective as topical BDP in the treatment of chronic hand Eczema and could be useful as an alternative treatment for severe chronic hand eczema in patients unresponsive to conventional treatment. Expand
9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial.
TLDR
9-cis-retinoic acid capsules have moderate activity and provide durable responses, but substantial toxic effects at higher doses limit its suitability as an anti-KS therapy. Expand
Successful Treatment of Chronic Hand Eczema with Oral 9-cis-Retinoic Acid
TLDR
9-cis-RA is a valuable drug when given at low doses to patients with chronic hand eczema in a pilot study in an exploratory open-label study. Expand
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial.
TLDR
9-cis-RA treatment can restore RAR-beta expression in the bronchial epithelium of former smokers, raising the possibility that this retinoid has potential chemopreventive properties in former smokers. Expand
Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer.
  • N. Rizvi, J. Marshall, +7 authors M. Hawkins
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1998
TLDR
9-cis-RA is a retinoid receptor pan agonist with a more favorable pharmacokinetic and toxicity profile than that observed with previously studied retinoids and merits further investigation. Expand
Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid.
  • V. Miller, J. Rigas, +8 authors R. Warrell
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1996
TLDR
9-cis RA is a novel compound that exploits a newly identified pathway of retinoid receptor biology that may be relevant to tumor cell proliferation and differentiation and recommended for single-agent trials utilizing a once-daily schedule of administration. Expand
Hand dermatitis: practical management and current concepts.
  • E. Epstein
  • Medicine
  • Journal of the American Academy of Dermatology
  • 1984
TLDR
With perceptive persistence, most chronic HD can be effectively controlled, and often it means restoring a social and economic outcast to a useful and happy life. Expand
Phase I trial of 9-cis retinoic acid in adults with solid tumors.
  • J. Kurie, J. S. Lee, +7 authors W. Hong
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1996
TLDR
Based on this study, the recommended Phase II dose of 9-cis retinoic acid in adult patients with solid tumors is 100 mg/m2/day administered in a divided dose twice daily, and Pharmacokinetic analysis revealed a reduction in peak 9- cis retinosic acid plasma levels with chronic administration. Expand
Vitamin A Enhances in Vitro Th2 Development Via Retinoid X Receptor Pathway1
TLDR
Data show that stimulation of the RXR pathway enhances Th2 development, perhaps by affecting the relative expression of pertinent transcription factors, cytokines, and cytokine receptors. Expand
Epidemiology of hand eczema in an industrial city.
  • B. Meding
  • Medicine
  • Acta dermato-venereologica. Supplementum
  • 1990
TLDR
A multiple logistic regression analysis revealed that the most important predictive factor for hand eczema was female sex, followed by occupational exposure, a history of asthma and/or hayfever and a service occupation, which was shown to be a long-lasting disease with a relapsing course. Expand
...
1
2
3
...